Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline

American Journal of Tropical Medicine and Hygiene

Volumn 80, Issue 6, 2009, Pages 956-963

  Debrah, Alexander Y ^a,b,c   Mand, Sabine ^a   Marfo Debrekyei, Yeboah ^c   Batsa, Linda ^c   Pfarr, Kenneth ^a   Lawson, Bernard ^b   Taylor, Mark ^d   Adjei, Ohene ^b   Hoerauf, Achim ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DOXYCYCLINE; IVERMECTIN; PLACEBO; VASCULOTROPIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GHANA; HUMAN; HYDROCELE; MAJOR CLINICAL STUDY; MALE; MICROFILARIASIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WOLBACHIA; WUCHERERIA BANCROFTI;

WOLBACHIA SP.; WUCHERERIA BANCROFTI;

EID: 66949124312     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.80.956     Document Type: Article

References (45)

1. Ottesen EA, 2000. The global programme to eliminate lymphatic filariasis. Trop Med Int Health 5: 591-594.
2. Addiss DG, Brady MA, 2007. Morbidity management in the global programme to eliminate lymphatic filariasis: a review of the scientific literature. Filaria J 6: 2. (Pubitemid 46470224)
3. World Health Organization, 2006. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 81: 221-232.
4. Eigege A, Richards FO Jr, Blaney DD, Miri ES, Gontor I, Ogah G, Umaru J, Jinadu MY, Mathai W, Amadiegwu S, Hopkins DR, 2003. Rapid assessment for lymphatic filariasis in central Nigeria: a comparison of the immunochromatographic card test and hydrocele rates in an area of high endemicity. Am J Trop Med Hyg 68: 643-646. (Pubitemid 38235089)
5. Jordan P, 1957. The fevers of Africa. 5. Clinical bancroftian disease in Tankanyika. Cent Afr J Med 3: 18-23.
6. Dreyer G, Nores J, Addis D, 1997. The silent burden of sexual disability associated with lymphatic filariasis. Acta Trop 63: 57-60. (Pubitemid 27121676)
7. Wegesa P, McMahon JE, Abaru DE, Hamilton PJ, Marshall TF, Vaughan JP, 1979. Tanzania filariasis project: survey methodology and clinical manifestations of bancroftian filariasis. Acta Trop 36: 369-377. (Pubitemid 10186417)
8. Mwobobia IK, Muniu EM, Kombe Y, Wamae CN, 2000. Hydrocelectomy: a proxy for hydrocele prevalence in coastal Kenya. Ann Trop Med Parasitol 94: 479-484. (Pubitemid 30639130)
9. DeVries CR, 2002. The role of the urologist in the treatment and elimination of lymphatic filariasis worldwide. BJU Int 89 (Suppl 1): 37-43. (Pubitemid 34228908)
10. Ottesen EA, 1992. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology 104 (Suppl): S71-S79.
11. Ottesen EA, 1980. Immunopathology of lymphatic filariasis in man. Springer Semin Immunopathol 2: 373-385. (Pubitemid 10089632)
12. Ottesen EA, Weiler PF, Lunde MN, Hussain R, 1982. Endemic filariasis on a Pacific Island. II. Immunologic aspects: immunoglobulin, complement, and specific antifilarial IgG, IgM, and IgE antibodies. Am J Trop Med Hyg 31: 953-961. (Pubitemid 12030527)
13. Debrah AY, Mand S, Toliat RM, Marfo-Debrekyei Y, Batsa L, Nuernberg P, Lawson B, Adjei O, Hoerauf A, Pfarr K, 2007. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 77: 601-608. (Pubitemid 351844277)
14. Ferrara N, 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55: 15-35. (Pubitemid 32094444)
15. Carmeliet P, 2000. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 6: 1102-1103.
16. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S, 2002. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51: 1635-1639. (Pubitemid 34826636)
17. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P, 2004. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53: 861-864. (Pubitemid 38270661)
18. Dvorak HF, Brown LF, Detmar M, Dvorak AM, 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
19. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF, 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
20. Esterre P, Plichart C, Huin-Blondey MO, Nguyen LN, 2005. Soluble cellular adhesion molecules, selectins, VEGF and endothelin-1 in patients with Wuchereria bancrofti infection and association with clinical status. Parasite Immunol 27: 9-16. (Pubitemid 40524988)
21. Debrah AY, Mand S, Specht S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Larbi J, Lawson B, Taylor M, Adjei O, Hoerauf A, 2006. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2: e92. (Pubitemid 44525727)
22. Turner JD, Mand S, Debrah AY, Muehlfeld J, Pfarr K, McGarry HF, Adjei O, Taylor MJ, Hoerauf A, 2006. A randomized, double- blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 42: 1081-1089.
23. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K, 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 273: 8413-8418. (Pubitemid 28168903)
24. Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA, 2006. Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 72: 161-171. (Pubitemid 44692751)
25. Gyapong M, Gyapong J, Weiss M, Tanner M, 2000. The burden of hydrocele on men in northern Ghana. Acta Trop 77: 287-294.
26. Meyrowitsch DW, Simonsen PE, Makunde WH, 1996. Mass DEC chemotherapy for control of bancroftian filariasis: comparative efficacy of four strategies two years after start of treatment. Trans R Soc Trop Med Hyg 90: 423-428. (Pubitemid 26335975)
27. Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 1998. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 351: 162-168. (Pubitemid 28037005)
28. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 2002. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347: 1841-1848. (Pubitemid 35417775)
29. Bernhard P, Magnussen P, Lemnge MM, 2001. A randomized, double-blind, placebo-controlled study with diethylcarbamazine for the treatment of hydrocoele in an area of Tanzania endemic for lymphatic filariasis. Trans R Soc Trop Med Hyg 95: 534-536. (Pubitemid 34947412)
30. Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH, 2003. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Ann Trop Med Parasitol 97: 827-838. (Pubitemid 38041382)
31. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW, 2003. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol (Berl) 192: 211-216. (Pubitemid 37491681)
32. Mand S, Marfo-Debrekyei Y, Dittrich M, Fischer K, Adjei O, Hoerauf A, 2003. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2: 3. (Pubitemid 38751368)
33. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A, 2005. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 365: 2116-2121. (Pubitemid 40826969)
34. World Health Organization, 1997. Chagas disease, leprosy, lymphatic filariasis, onchocerciasis: prospects for elimination. TDR/ Gen 97: 17-22.
35. Michael E, Bundy DA, Grenfell BT, 1996. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitol 112: 409-428. (Pubitemid 26126021)
36. Ottesen EA, Duke BO, Karam M, Behbehani K, 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75: 491-503. (Pubitemid 28099975)
37. Addiss DG, Brady MA, 2007. Morbidity management in the global programme to eliminate lymphatic filariasis: a review of the scientific literature. Filaria J 6: 2. (Pubitemid 46470224)
38. Faris R, Hussain O, El Setouhy M, Ramzy RM, Weil GJ, 1998. Bancroftian filariasis in Egypt: visualization of adult worms and subclinical lymphatic pathology by scrotal ultrasound. Am J Trop Med Hyg 59: 864-867. (Pubitemid 29028912)
39. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K, 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425. (Pubitemid 27235412)
40. Peixoto CA, Figueiredo-Silva J, 2001. Fine structure of intrascrotal lymphatic vessels infected by Wuchereria bancrofti adult worms. J Submicrosc Cytol Pathol 33: 125-131. (Pubitemid 33610630)
41. Norões J, Addiss D, Santos A, Medeiros Z, Coutinho A, Dreyer G, 1996. Ultrasonographic evidence of abnormal lymphatic vessels in young men with adult Wuchereria bancrofti infection in the scrotal area. J Urol 156: 409-412. (Pubitemid 126445353)
42. Saaristo A, Tammela T, Timonen J, Yla-Herttuala S, Tukiainen E, Asko-Seljavaara S, Alitalo K, 2004. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 18: 1707-1709. (Pubitemid 39561658)
43. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW, 2003. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 111: 717-725. (Pubitemid 36278590)
44. Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Alitalo K, 2001. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med 7: 18-22. (Pubitemid 33718078)
45. Ottesen E, Weil GJ, 2004. Towards a strategic plan for research to support the global programme to eliminate lymphatic filariasis. Am J Trop Med Hyg 71 (Suppl): 1-2.